Future Perspectives in the Treatment of Chronic Lymphocytic Leukemia

September 11th 2025

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.

Elizabeth Shpall, MD

May 29th 2019

Recapping A Quarter Decade of Chronic Myeloid Leukemia Therapy

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Chronic myeloid leukemia was once known as a deadly disease, renowned for its difficulty to treat.

September 2nd 2025

Immunotherapy Approaches in AML

Jorge Cortes, MD, believes that, despite the rapid improvements made in CML treatment, there is always more to be done to help patients.

Naval Daver, MD

January 17th 2019

Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.

Roman Fabbricatore

August 19th 2025

National ICE-T Conference Aims to Make CAR T Safer and More Available

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

August 2nd 2025

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Leading experts gathered in Orlando, Florida, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

Related Content

September 11th 2025

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.

Elizabeth Shpall, MD

May 29th 2019

Recapping A Quarter Decade of Chronic Myeloid Leukemia Therapy

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

September 2nd 2025

Immunotherapy Approaches in AML

Jorge Cortes, MD, believes that, despite the rapid improvements made in CML treatment, there is always more to be done to help patients.

Naval Daver, MD

January 17th 2019

Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Roman Fabbricatore

August 19th 2025

National ICE-T Conference Aims to Make CAR T Safer and More Available

No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.

August 2nd 2025